Citizens analyst Reni Benjamin downgraded Werewolf Therapeutics (HOWL) to Market Perform from Outperform.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HOWL:
- Wedbush downgrades Werewolf Therapeutics to Neutral on challenging path
- Werewolf Therapeutics downgraded to Neutral from Outperform at Wedbush
- Werewolf Therapeutics price target lowered to $4 from $10 at H.C. Wainwright
- Clinical Momentum and Platform Validation Drive Undervalued Upside at Werewolf Therapeutics
- Werewolf Therapeutics Updates Pipeline and Outlines 2026 Priorities